Monday, November 12, 2012
GenSpera Inc., of San Antonio, presented interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers. The main conclusions are that G-202 appeared to be well tolerated when administered via the recommended dosing regimen and that it should be evaluated in Phase II studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.